• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Exploring the food-gut axis in immunotherapy response of cancer patients

    2020-10-29 02:03:34EddaRussoGiuliaNanniniMonicaDinuGiudittaPagliaiFrancescoSofiAmedeoAmedei
    World Journal of Gastroenterology 2020年33期

    Edda Russo, Giulia Nannini, Monica Dinu, Giuditta Pagliai, Francesco Sofi, Amedeo Amedei

    Abstract Nowadays, immunotherapy is widely used to treat different cancer types as it boosts the body's natural defenses against the malignancy, with lower risk of adverse events compared to the traditional treatments. The immune system is able to control cancer growth but, unfortunately, many cancers take advantage of immune checkpoints pathways for the immune evasion. An intricate network of factors including tumor, host and environmental variables influence the individual response to immune checkpoints’ inhibitors. Between them, the gut microbiota (GM) has recently gained increasing attention because of its emerging role as a modulator of the immune response. Several studies analyzed the diversities between immunotherapy-sensitive and immunotherapy-resistant cohorts, evidencing that particular GM profiles were closely associated to treatment effect. In addition, other data documented that interventional GM modulation could effectively enhance efficacy and relieve resistance during immunotherapy treatment. Diet represents one of the major GM determinants, and ongoing studies are examining the role of the food-gut axis in immunotherapy treatment. Here, we review recent studies that described how variations of the GM affects patient’s responsivity to anti-cancer immunotherapy and how diet-related factors impact on the GM modulation in cancer, outlining potential future clinical directions of these recent findings.

    Key words: Immune response; Immunotherapy; Programmed cell death protein 1; PD-L1; Cancer; Gut microbiota; High fiber diet

    INTRODUCTION

    The role of the immune system in tumor control has been a topic of discussion for many years but the current opinion is that cancer is a genetic-based disease that arise when somatic cells acquire multiple mutations overcoming the barriers that normally keep them under control (see the cancer immunoediting, well reviewed by Schreibeet al[1]). The host immune system plays many roles in cancer prevention such as: (1) Suppression virus-induced tumors contrasting the viral infections; (2) Prevention of the setting of an inflammatory environment pro-tumorigenesis; and (3) Elimination of tumor cells that express ligands for receptors active on innate immune cells and tumor antigens recognized by the adaptive immune cells[2]. On the other side, cancer cells, thanks to their genetic instability, can escape from immunosurveillance and potentially lead to cancer. Therefore, a targeted immunotherapy acts as an innovative anti-cancer approach, able to boost the host anti-tumor immune response, and, concomitantly, help to “hit” recurrence mechanisms and cancer resistance[3].

    Recent clinical and preclinical (in vitroand animal models) studies have revealed that the gut microbiota (GM) is implicated in modulating the efficacy and toxicity of anti-cancer treatment, like chemotherapy and immunotherapy[4]. The GM is a conglomerate of microorganisms composed of trillions of microbes, including viruses, bacteria, fungi and protozoa, with the greater population harbouring in the intestine. It is composed of two predominant phyla, namedFirmicutesandBacteroidetes(approximately 90% of the total bacteria), while the remaining 10% are partitioned betweenVerrucomicrobia,ProteobacteriaandActinobacteria[5]. GM plays an important role in host nutrition, metabolism and physiology, as well as the protection against pathogens and the development of the immune system. Notably, if on the one hand the microbiota participates in the maturation of the host's immunity, on the other hand its distribution is in turn modulated by the host's immune system[6]. In addition, the microbiota helps in aliment digestion from otherwise indigestible molecules and generates essential vitamins (K and B)[7]. Moreover, the intestinal dysbiosis (defined as a disequilibrium of the microbiota composition) has been found to be linked to the tumor initiation and progression[8]. Recent studies documented that anomalous microbiota-host interactions are associated with various neoplasia like gastric, colorectal and liver cancer[9,10]. Furthermore, a dysbiotic gut microbiota can also impact the tumor therapeutic outcome, with the latter deeply associated with the GM capacity to metabolize anti-tumoral molecules, as well as to regulate inflammation pathways and host's immune response[9]. In particular, the GM is able to influence anti-tumor immune responses through innate and adaptive immunity and the therapeutic response may be enhanced through its modulation[11,12].

    Nowadays, it is of utmost importance to improve the therapeutic outcome of patients, developing novel approaches to modulate the GM by strategies without any associated risk, as dietary intervention[13]. In general, diet has a direct role in cancer prevention, prognosis and therapies, deeply supported by animal model, epidemiological and clinical studies. Concerning nutritional patterns, diets rich in plant-based foods such as vegetables, fruit, legumes and whole grains are known to have beneficial effects due to the significant amount of fiber and antioxidant compounds, which exert an inhibitory effect on several carcinogenic pathways, including the carcinogens’ activation, cell cycle regulation, cell signaling, angiogenesis and inflammation[14]. On the contrary, a high intake of refined cereals, sugar-sweetened beverages, alcohol, red and processed meat seems to have detrimental effects, deriving from the large amount of simple sugars, salt, ethanol metabolites, saturated and trans fatty acids, which are related to pro-inflammatory effects, and alterations to cell proliferation and apoptosis[15,16]. Thus, healthy dietary habits are not only useful for weight control, but indirectly influences cancer risk since there are increasing evidence on the link between obesity and carcinogenesis. The obesity is associated with inflammation, endocrine and metabolic alterations, which increase cell proliferation and exert anti-apoptotic effects (in other words, the tumor cells do not self-destruct even after serious DNA damage)[17]. While nutritional problems such as obesity can induce carcinogenesis, cancer therapies can promote both malnutrition and weight loss. In cancer patients, weight loss can be caused by several factors, such as low energy intake, deficiency in nutrient absorption, tumor-induced catabolism and treatment side effects, resulting in therapeutic failure and poor quality of life[18]. Therefore, it seems clear that proper nutrition in cancer patients is crucial not only to prevent the malnutrition risk, but also to improve the therapy effectiveness. Indeed, recent studies suggest that diet plays a crucial role also in the treatment of cancer patients, due to the chemo-protective effects of some foods - such as omega-3 fatty acids or polyphenolic compounds - and the synergistic effect in suppressing cell proliferation[19]. On the other hand, some foods can also generate toxicity or interact with a particular type of treatment such as oral chemotherapy[16]. Therefore, it appears strategical to implement both personalized pharmacological and non-pharmacological interventions taking into account not only the histopathological cancer characteristics but also the environmental factors and the nutritional requirements of patients. Interestingly, as previously reported, diet components could act on cancer treatment also indirectly by changing the GM composition[13]. Based on the “food-gut” axis, this review aims to discuss the emerging link between immunity, diet and GM with a special focus on immunotherapy (using the immune checkpoint inhibitors - ICIs), along with recent observations that could connect dietary-related modulation of microbiota with anti-cancer therapies outcome.

    “MICROBIOME-IMMUNITY AXIS” IN CANCER IMMUNOTHERAPY AND NEW INSIGHTS ON THE IMPACT OF DIETARY FACTORS

    Regarding the GM impact on the host immune system, the current years witnessed the publication of marking breakthrough, profoundly correlating the patients' microbiota profile with the positive outcome of cancer immunotherapy using the ICIs[20], Chimeric antigen receptor T cells (CAR-T) and vaccines[21]. ICIs are one of the main current therapeutic anti-cancer strategies[22]. Cancer cells presented on their surface immune checkpoint molecules that interact with CD8+T cells, leading to tumor escape from immune system cells[23]. ICIs inhibit the interactions between molecules of the immune checkpoint and inhibitory T cellular receptors. Currently, the most adopted ICIs are monoclonal antibodies acting towards the programmed cell death protein 1 (PD-1) and its PD-L1 Ligand[24]. The food and drug administration (FDA) has approved several proteins programmed for PD-1 and PD-L1 in the treatment of solid and haematological malignancies.

    As far as it is concerned CAR-T, CAR technology was first reported in 1993 when Zelig Eshhar and coll. transduced T cells with chimeric genes encoding single-chain antibodies linked to a transmembrane region and an intracellular domain encoding the signalling adaptor for the T cell receptor[25]. CAR-T cells, currently approved in haematological malignancies, are autologous T-cell re-directed towards tumor-specific antigen. CAR-T cells contain signalling domains involved in T-cell activation as CD3ζ, CD28, 4-1BB, ICOS, and OX40. A second generation CAR connects an antigen-binding domain to the T-cell signalling domain coupled to the intracellular signalling domain of a costimulatory moleculee.g., CD28. CAR-T cell constructs may contain multiple signalling domains, that favour activation and durability of CAR-T cells, permitting therefore the implementation of the effector functions of a CAR T-cells MHCindependent[26-28]. In August 2017, the FDA approved CAR T-cells directed against CD19 for the treatment of acute lymphoblastic leukemia (ALL) and then axicabtagene ciloleucel to treat R/R large B-cell lymphoma in October 2017[26,27,29-31].

    In spite of promising clinical outcomes obtain with immune checkpoint blockade and CAR therapies, the results of therapeutic vaccination against established tumours proved to be only in part positive, with clinical benefit for cancer's patients. However, as well elucidate from Melief and colleagues, the suboptimal vaccine design and the presence of an immunosuppressive tumor microenvironment are the reasons for the shortage of cancer eradication[32].

    However, not all patients with cancer may undergo immunotherapy as some of them are resistant to therapy[33]. In the last years there has been a growing interest in identifying the immune properties of the cancer microenvironment including the characterization of tumor infiltrating lymphocytes (TILs) that seems to play an important role in response to checkpoint inhibition[34].

    Recent evidence of the interaction between specific microbes and ICIs are documented in mouse models studies[35-37], suggesting that efficacy of checkpoint blockade through PD-1 and CTLA-4 pathways could be improved through microbiota modulation (Figure 1).

    As early as 2015, Sivan and coll. observed melanoma growth in mice with distinct microbiota profiles and noticed differences in anti-tumor immune-mediated response, especially tumor-specific T cell responses and intra-tumoral CD8+ T cell accumulation. Interestingly this different response was reset upon cohousing or after fecal microbiota transplantation (FMT)[35]. In same time, a study analysed various data from patients with different neoplasia, including the antibiotic therapy when starting a CTLA-4 treatment[36]. The result showed that bacteria belonging to the generaBacteroidesandBurkholderiawere associated to the anti-tumor action of the microbiota. In response to these bacteria genera, innate immune cells release IL-12 that may activate the adaptive immune response, thus stimulating T cells. In order to endorse these data, microbes were transferred directly in germ-free mice or indirectly, by giving them feces enriched inBacteroidesof Ipilimumab-treated patients. In all cases, the response to the checkpoint inhibitors was improved[36].

    Similarly, in a different study, the GM analysis of patients who positively responded to PD-1 blockade showed an enrichment inCollinsella aerofaciens, Enterococcus faecium and Bifidobacterium longum. When responders’ fecal samples were transferred to germ-free mice, a slower tumor growth and improved therapeutic effects were observed, compared to mice receiving non-responders’ fecal samples. In addition, an increase in CD8+T cells and a decrease in Tregs (Regulatory T cells) in the tumor microenvironment was observed[38].

    These preliminary mouse studies endorsed the critical GM role in tumor ICIs therapy and encouraged clinical pursuits to determine the influence of the microbiota on human ICIs-based therapies.

    Routy and coll. demonstrated that primary resistance to ICIs can be associated to anomalous GM profiles showing that anti-PD-1/PD-L1 treatment was more efficient in patients with advanced epithelial tumor that did not receive antibiotics, compared with the outcome of those receiving antibiotics[20]. This result underlines that antibiotic treatment is able to destroy the gut microbiota, impairing immune checkpoint blockade response. In particular, whole metagenomic sequencing analyses in fecal samples, collected at diagnosis, revealed that patients responding to PD-1 blockade had different GM composition, rich inAkkermansiaandAlistipes. In addition, before the anti-PD-1 therapy, germ-free mice were treated with FMT using fecal samples from responding patients and immune response was found to be enhanced, while immune response of germ-free mice treated with FMT from non-responders was restored by oral supplementation ofAkkermansia muciniphila. These bacteria induced the efficacy of PD-1 blockade in an IL-12-dependent way by augmenting the enrollment of CXCR3+CCR9+CD4+T cells into mouse tumor beds[20].

    Gopalakrishnan and coll. analysed oral and gut microbiota of a cohort of 112 metastatic melanoma patients under anti-PD-1 therapy. The analysis of systemic immune responses revealed that patients whose gut samples where enriched in

    Clostridiales,Ruminococcaceae, orFaecalibacteriumhad more effector T cells (CD4+and CD8+) in the peripheral blood and a protected cytokine response to anti-PD-1 treatment, while patients with abundance ofBacteroidaleshad higher frequencies of Tregs, with a diminished cytokine response[39]. Immune profiling indicated an enhanced anti-tumor and systemic immunity in responding melanoma patients with a beneficial intestinal bacterial flora, as well as in germ-free mice receiving FMT from responding patients.

    A recent study analyzed patients with non–small cell lung cancer undergoing Nivolumab therapy. The higher diversity of fecal microbiota before and after anti-PD-1 therapy was related with prolonged “progression-free survival time” compared with the lower GM diversity[40]. Furthermore, patients responding to Nivolumab therapy showed higher diversity of enteric microbiota at baseline, which sustained stable composition during therapy[40].

    Finally, a study of Tanoue and coll. has identified 11 healthy human associated bacterial strains that induce IFN-γ CD8+T cells and are effective at inhibiting growth of colorectal cancer if used with ICIs[41].

    Figure 1 Gut microbiota impact on the efficacy of programmed cell death protein 1 blockade. Specific gut microbiota profiles correlates with response to programmed cell death protein 1 (PD-1) blockade in tumor patients. Fecal microbioma transplantion (FMT) from responders into mice, improve responses to anti-PD-1 treatment and correlated with increased anti-cancer CD8+ cells in the tumour environment. Mice receiving FMT from non-responders’ patients did not respond to anti-PD-1 therapy, and tumour microenvironment is enriched of immune suppressive CD4+ regulatory T cells. PD-1: Programmed cell death protein 1; FMT: Fecal microbioma transplantion; Tregs: Regulatory T cells.

    However, enteric microbiota is also able to induce toxicity to the immune checkpoint blockade. This effect was firstly observed in animal models and then in cohorts of patients[42-44]. The microbiota taxa associated in both toxicity and response to ICIs has been identified within theFirmicutesphylum andRuminococaceaefamily[39,42,43]. On the contrary, the microbiota taxa lacking response to ICIs have been identified within theBacteroidalesorder, but a higher richness in these taxa commonly diminish the incidence of toxicity[39,42,43].

    In addition, the preliminary result of the first clinical study on the impact of the food-gut axis in the relationship between GM and response to anti-PD-1 checkpoint inhibitors reported that diet and supplements might have an effect on the patient’s responsivity to anti-cancer immunotherapy, probably due to the modulation of their intestinal microbiome[45]. The analysis of fecal samples from 113 melanoma patients under anti-PD-1/PD-L1 therapy confirmed that higher microbial diversity might be associated with a positive response to treatment. Participants provided information about their dietary habits and use of probiotic supplements but only 40% of them reported to have effectively taken the supplements. Moreover, researchers found that a high fibers’ consumption (including fruits, vegetables and whole grains) is positively linked with the presence of microorganism associated to a good anti-PD-1 treatment response in previous studies[45]. On the contrary, a diet with high consumption of sugars and processed meat was negatively linked with these species. In particular, an enrichment ofRuminococcaceaefamily was associated with better therapy response, whileBacteroidalesbacteria were associated to poorer response. Furthermore, data from a subset of 46 patients treated with anti-PD-1 immunotherapy (Pembrolizumab or Nivolumab), showed that patients who consumed a high-fibers’ diet were about five times as likely to respond to anti-PD-1 therapy compared to patients who consumed a low-fibers’ diet. Surprisingly, the consumption of probiotic supplements was linked to less gut bacteria diversity[45].

    Given these results on the potential importance of fibers in the dietary survey, the same group of researchers is also starting a controlled diet trial, comparing melanoma patients eating a healthy, high-fibers’ diet to those eating a healthy diet but without a high-fibers’ component during their immunotherapy treatment (NCT03950635).

    On the other side, the link between dietary fibers and immunity could be the shortchain fatty acids (SCFAs), which are produced by fiber-fermenting bacteria and are the primary nutrient source for gut enterocytes. A very recent work of Coutzac and coll. showed that systemic microbial SCFAs’ modulate anti-CTLA-4-induced immune responses and its antitumor efficacy[46]. In particular, they demonstrated that, in mice, butyrate stops upregulation of CD80/CD86 on DC and ICOS on T cells, and accumulation of tumor specific T cells and memory T cells lead by anti-CTLA-4. As in mice, Coutzac’s group provided evidence that high butyrate was associated with less accumulation of memory and less ICOS induction on T cells in metastatic melanoma patients treated with anti-CTLA-4. This study supplies a new vision on the relationship between the GM composition GM and the clinical response to anti-CTLA-4viamicrobiota-derived metabolites.

    A very recent communication (ASCO-SITC Clinical Immuno-Oncology Symposium, February 2020), showed that cancer patients who were eating more fibers, fruits, vegetables, and whole grains had an increased abundance of pro-response and fiberfermenting bacteria. Of note, patients who consumed a high-fibers’ diet as a habitual diet were nearly five times more likely to respond to PD-1-based immunotherapy and had significantly improved progression-free survival[47]. The researchers also studied the synergy between the GM signature and dietary fiber intake. They found that patients most likely to respond to immunotherapy are those who have both “beneficial” bacteria and a fiber-rich, plant-based diet needed to feed those bacteria. The next step is to observe whether GM modulation with a controlled feeding study can influence immune response.

    TRINITY CONNECTION: DIET, GUT MICROBIOTA AND IMMUNE RESPONSE

    To date, most of the information regarding the GM modulation of the immune system through the food –gut axis comes from studies on germ-free animal models. The data showed that nutrients play a considerable role in shaping the GM composition, while the composition and GM products influence the development of the host immune system and the inflammatory response (Figure 2). At the same time, the immune system has developed multiple strategies to maintain its symbiotic relationship with commensal microbes, making the interaction between microbiota and immunity bidirectional[48].

    The influence of dietary habits on the GM composition and functionality has been widely investigated and many studies have shown that dietary changes rapidly alter the GM[49,50]. In animal models, the consumption of a western diet rich in sugar, salt and fat and low in fibers was associated with changes in microbial composition, gene expression and metabolic pathways after only one day and led to an increase in adiposity in two weeks[51]. In humans, the transition from a plant-based to an animalbased diet has resulted in a significant increase in β-diversity nearly after 24 h, with a decrease in the faecal levels of carbohydrate fermentation metabolites and an increase in amino acid fermentation metabolites[49]. GM alterations after short-term dietary interventions, however, seem to be transient and generally do not persist for more than a few days[52,53]. Long-term diets, on the other hand, have a greater influence on the GM, and habitual diet has been shown to be associated with a distinct intestinal enterotype[54]. In particular, the African diet, high in fibers, has been associated with the enterotypePrevotella, while the Western diet, rich in animal proteins and fat, has been associated withBacteroidesenterotype[55,56]. Further studies have confirmed these findings, supporting the hypothesis that diets rich in fermentable nutrients may induce an increase in beneficial bacteria such asBifidobacteriaandEubacteria, while diets rich in animal proteins and saturated fatty acids and low in fibre, increase the abundance of potentially unhealthy bacteria such asBacteroidesandClostridia[57].

    Figure 2 Relationship between dietary factors, microbiota and immune response. SCFAs: Short-chain fatty acids; TLR4: Toll-like receptor 4; TMAO: Trimethylamine N-oxide; Tregs: Regulatory T cells.

    To date, the content, quantity and type of fibers are among the most commonly accepted determinants of the GM composition[57]. Accumulated evidence has shown that fibers’ intake is associated with increased abundance of potentially beneficial species such asAkkermansia municiphiliaandRoseburiaspp, which ferment dietary fibers and produce SCFAs (acetate, propionate and butyrate). As previously reported, SCFAs are important for maintaining epithelial barrier function and regulating mucosal and systemic immunity[58]. In addition, SCFAs modulate cytokines’ production and reduce oxidative DNA damage. While the SCFAs’ impact on intestinal epithelial cells refer to their role as an energy source, the effects on the immune system are mediated by the interaction with the G-protein coupled receptor 43 (GPR43) and by the inhibition of the production of histone deacetylase[59]. This inhibition promotes T cell differentiation towards regulatory T cells (Tregs), able to produce the antiinflammatory interleukin-10 (IL-10) and other molecules such as CTLA-4 and tumor growth factor-β (TGF-β)[60]. The role of Tregs in maintaining the immunological selftolerance and in safeguarding the immune balance at the sites of environmental exposed surfaces is therefore crucial and recent studies suggested Tregs as an attractive target for T-cell-based immunotherapies[60]. Bacteria involved in the response to these therapies resemble those eating and secreting mucin (e.g.,Akkermansia municiphilia, Bifidobacterium longumandFaecalibacterium prausnitzii), which maintain barrier integrity and improve ICIs’ efficacy. The abundance of these bacteria, as demonstrated by several studies, is influenced by dietary factors such as fibers and proteins’ intake[61].

    Moreover, the fibers can influences the immune systemviathe synthesis of glycans by the bacteria of theBacteroidetesphylum. The commensal bacteriaBacteroides fragilis, for example, produce a particular immunosuppressive glycan, the polysaccharide A, which works as a toll-like receptor 2 (TLR2) ligand and promote Tregs’ differentiation[62].Bacteroides fragilisalso induces an IL-10 response in intestinal T cells, preventing the expansion of Th (helper)17 cells and the potential damage to the mucosal barrier[63].

    In addition to fibers, other nutrients are involved in modulating the immune system, either directly, by interacting with the host through the intestinal immune system, or indirectly, by modulating the GM composition. Omega-3 fatty acids, for example, modulate the inflammation by inducing a transient increase in some SCFAsproducer bacterial genera and by interacting with the G protein-coupled receptor 120 (GPR120)[64]. GPR120 is primarily expressed by the macrophages, and binding with omega-3 fatty acids supress the production of tumor necrosis factor alpha (TNF-α) and IL-6, decreasing the macrophage-induced tissue inflammation. Similarly, saturated fatty acids, proteins and vitamins influence the host inflammatory responses through the TLR4 activation[65], the increase in trimethylamine-n-oxide (TMAO) synthesis and the expression of mucin 2[66,67], and the induction of tolerogenic dendritic cells and Tregs’ differentiation, respectively[68].

    Finally, the use of probiotics and prebiotics has also been studied in relation to the GM modulation and the immune system. Although some evidence suggest that their consumption can restore innate and adaptive immunity, human supplementation trials have produced conflicting results[69,70]. Diet supplement of microbiota may be a double-edged sword as potential risks of bacteremia, sepsis, and multi-organ failure associated with the use of probiotics have been reported, especially in immunecompromised populations or in subjects with metabolic hyper-inflammatory conditions[71]. Despite of that, probiotics’ administration in multiple trials has shown beneficial effects on ameliorating diarrhea and other gut-related damages following anti-cancer therapy, thus re-establishing a healthy GM composition[72].Lactobacilliwere administrated to cancer patients to re-populate the compromised patients’ GM, thus re-establishing the levels and functionality of the commensal bacteria, depleted after the treatments[73]. Regardless the beneficial effects, larger and controlled clinical trials are further needed to truly endorse both the efficacy and the safety of administering selected species of probiotics during or following anti-cancer treatments. Therefore, as previously suggested, a safer way to modulate the GM could be through dietary interventions or supplementation with prebiotics such as oligosaccharides, fructans, and galactans, which are known to increase the proportion of potentially beneficial bacteria (e.g.,Bifidobacteria) and the production of SCFAs.

    FUTURE STRATEGIES TO IMPROVE THE RESPONSE TO IMMUNOTHERAPY THROUGH THE FOOD-GUT AXIS

    Based on the aforementioned results, the GM profile might be studied as a predictive or prognostic biomarker for anti-cancer treatment efficacy. As previously stated, higher diversity in the intestinal microbiota was associated with a better response rates to immune checkpoint blockade[39], which suggests that assessing community richness and proportion of “detrimental” and “beneficial” bacterial, prior to immunotherapy, might be crucial for the outcome trend and treatment decision. In the next future, the GM profile could be coupled with other known parameters related to outcome such as cancer mutational burden and T cell infiltration. Moreover, GM composition could be used to indicate additional interventionsviathe microbiota to improve immunotherapy effectiveness or alternatively decrease therapy related toxicity.

    However, the role of external influencers, such as medications, probiotics, prebiotics and postbiotics’ administration and dietary pattern on the GM modulation and the potential need to monitor these items during cancer therapy, have to be thoroughly investigated.

    In order to favour the expansion of beneficial bacteria or, conversely, “starving” detrimental bacteria, adjunctive therapeutic strategies, as preparative regimens (viadietary supplementation) prior to modulation of the gut microbiota, could be considered as upcoming ways to increase the efficacy of primary cancer immunotherapy (Figure 3).

    The administration of beneficial or immune-potentiating probiotic, provided as an immunotherapy adjuvant, offers a more achievable system of microbial manipulation in the clinical setting. Probiotics are inexpensive and are generally regarded as safe. In addition, the genetic manipulation of the microbes is a strategy that alters the bacterium’s existing capacities through the insertion of new genes in order to improve beneficial properties[74]. Moreover, in preclinical experiments, some phages have been already used to reduce pathogenic microbes in the commensal community, and could be further engineered to target strains efficacy[74]. Clinical trials to evaluate the impact of probiotics’ administration on treatments with checkpoint inhibitors have been initiated[75]. Notably, a double-blind clinical trial in colorectal cancer, revealed the positive effects of the probioticLactobacillus johnsoniion the GM composition[76]. In addition, a preoperative probiotic therapy withSaccaromices bulardiiinduced downregulation of pro-inflammatory cytokines within the colonic mucosa, with lower IL-10, IL-1β, and IL-23A mRNA levels[77]. This last result proved that probiotic administration could influence the local immunity. An ongoing protocol for patients with stage I-III breast cancer is actually analysing the effects of probiotics on CD8+T cell infiltrate (NCT03358511). Furthermore, a research using the keywords “cancer”, “probiotics” and immunotherapy returned three ongoing studies from the website http://www.clinicaltrials.gov. Especially, the BISQUIT study (NTC03870307) is a phase-II randomized protocol of the use of pre-and probiotics during the definitive treatment of chemotherapy-radiotherapy for patients with localized anal canal squamous cell cancer (ACSCC). The aim is to increase the effectiveness of conventional treatment. ACSCC is, in many cases, a virus-associated tumor and therefore potentially immunogenic; immunotherapy is a promising strategy in ACSCC, so pre- and probiotics stimulating the immune system through the GM modulation, might improve oncological outcomes.

    Concerning prebiotics, in theory, if they are administered to the immunotherapy and consequently lead to the growth of beneficial microbes, they could have a helpful impact on rebalancing the intestinal microbiota inducing the host to react favourably to immunotherapies. The dietary supplementation with plant polysaccharide inulin as prebiotic has already revealed an increase ofBifidobacteriumandFaecalibacteriumspecies, previously associated with immunotherapy positive response[78]. Dietary fibers have also shown to induce a decrease in the abundance of immune-promotingF. prausnitzii[79].

    Figure 3 Potential strategies to shaping the gut microbiota through the “food- gut axis” and enhance immune checkpoint inhibitors’ response. In order to obtain a favourable microbiota modulation, adjunctive therapeutic strategies, as preparative regimens (via prebiotics, prebiotics, postbiotics or dietary supplementation) could be considered as upcoming ways for improving the efficacy of immunotherapy response. PD-1: Programmed cell death protein 1.

    Dietary interventions, having a low cost and safe profile, represent a straightforward opportunity for studying the association of microbiota and downstream immune manipulation in tumor. As previously reported, the literature in this field has suggested the responsiveness of particular taxa and their induced metabolites to several immune parameters and nutrients and provides exploratory insight into how dietary modulation could impact the intestinal microbiome and immune health[80,81], with parallels that can be drawn in the immunotherapy. Interestingly, a very recent study revealed that dietary deprivation of non-essential aminoacids improved anti-PD-1 immunotherapy in a mouse model of colon cancer[82].

    Finally, studies show that some nutrition formulation called “immunonutrients” containing essential aminoacids, omega-3 fatty acids, SCFAs and nucleotides could induce particular effects on immune system. Nowadays, these new developed formulas have improved outcome in tumor patients receiving chemo-radiotherapy, decreasing acute toxicity and modulating the immune and inflammatory response.

    Immunonutrition, defined as a modulation of the immune system provided by specific interventions that modify dietary nutrients, is an emerging field in oncology, and further research is needed, especially focusing on its effects in cancer immunotherapy[83,84]. The combination of immunotherapies with the support of immunonutrition may provide future therapeutic approaches.

    CONCLUSION

    In the past decade, immunotherapy propelled the advancement of oncology therapeutics. However, only in the very recent few years we have gained significant insights into the role of GM in cancer immunotherapy response, giving new alternative explanations on patients’ resistance acquisition.

    There is also evidence that the food-gut axis is involved in the modulation of gut microbiota, resulting in synergistic effects during cancer immunotherapy. The first clinical trials on dietary modulation of the microbiota involving cancer patients undergoing immunotherapy are now ongoing, giving further opportunities to improve efficacy and relieve resistance.

    Further investigations should determine the bacterial combination pools needed to help the anti-cancer response and how to develop such combinations and, in addition, the optimal dietary strategies to enhance the immunotherapy strategies, modulating the intestinal microbiota.

    ACKNOWLEDGEMENTS

    The authors thank Dr. Elisangela Miceli, PhD for her English language revision.

    97在线视频观看| 99热精品在线国产| 日本一二三区视频观看| 国产精品一区二区性色av| 久久久久免费精品人妻一区二区| 高清毛片免费看| 国产淫片久久久久久久久| 午夜亚洲福利在线播放| 国产精品一及| 九九在线视频观看精品| 久久这里有精品视频免费| 国产单亲对白刺激| 亚洲五月天丁香| 成人国产麻豆网| 国产精品久久久久久久电影| 日韩视频在线欧美| 桃色一区二区三区在线观看| 一边摸一边抽搐一进一小说| 一边摸一边抽搐一进一小说| 久久久久网色| 美女 人体艺术 gogo| 久久午夜亚洲精品久久| 亚洲最大成人av| 午夜福利在线在线| 国产黄片美女视频| 免费av观看视频| 成人午夜精彩视频在线观看| 国产精品电影一区二区三区| av专区在线播放| 久久久欧美国产精品| 91狼人影院| 国产精品人妻久久久久久| 色尼玛亚洲综合影院| 日本撒尿小便嘘嘘汇集6| 精品欧美国产一区二区三| 男人的好看免费观看在线视频| 性插视频无遮挡在线免费观看| 校园人妻丝袜中文字幕| 成年女人永久免费观看视频| 舔av片在线| 哪里可以看免费的av片| 午夜亚洲福利在线播放| 精品一区二区三区视频在线| 在线观看午夜福利视频| 久久精品夜色国产| 色尼玛亚洲综合影院| 赤兔流量卡办理| 人人妻人人澡人人爽人人夜夜 | 亚洲第一电影网av| 美女被艹到高潮喷水动态| 黄色一级大片看看| 欧美精品一区二区大全| avwww免费| 精品久久久久久久久av| av视频在线观看入口| 精品一区二区三区视频在线| 人妻少妇偷人精品九色| 人妻久久中文字幕网| 日韩大尺度精品在线看网址| 看免费成人av毛片| 12—13女人毛片做爰片一| 亚洲成人中文字幕在线播放| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 国产伦精品一区二区三区四那| 熟妇人妻久久中文字幕3abv| 不卡一级毛片| 97人妻精品一区二区三区麻豆| 99热只有精品国产| 亚洲精品自拍成人| 亚洲欧洲国产日韩| 亚洲精品乱码久久久久久按摩| 26uuu在线亚洲综合色| 亚洲精品粉嫩美女一区| 熟女人妻精品中文字幕| 欧美高清成人免费视频www| 男女啪啪激烈高潮av片| 成人特级av手机在线观看| 春色校园在线视频观看| 久久精品国产亚洲网站| 亚洲在线自拍视频| 尾随美女入室| av.在线天堂| 久久热精品热| 免费av毛片视频| or卡值多少钱| 久久久久九九精品影院| 成人鲁丝片一二三区免费| 亚洲av成人精品一区久久| 91精品一卡2卡3卡4卡| 你懂的网址亚洲精品在线观看 | 在线观看av片永久免费下载| 男女下面进入的视频免费午夜| 久久久久久久午夜电影| av卡一久久| 色视频www国产| 欧美极品一区二区三区四区| 美女被艹到高潮喷水动态| 欧美不卡视频在线免费观看| 日韩欧美 国产精品| 国产精品久久久久久精品电影| 国产视频首页在线观看| 99riav亚洲国产免费| 久久精品国产99精品国产亚洲性色| 老女人水多毛片| 久久久久久久久久成人| 亚洲欧美精品自产自拍| 久久精品久久久久久噜噜老黄 | 亚洲欧美精品自产自拍| 亚洲欧洲国产日韩| 青青草视频在线视频观看| 给我免费播放毛片高清在线观看| 亚洲精品456在线播放app| 久久久久久久久久久丰满| 大又大粗又爽又黄少妇毛片口| 日韩,欧美,国产一区二区三区 | 欧洲精品卡2卡3卡4卡5卡区| 国产成人午夜福利电影在线观看| 九九在线视频观看精品| 18禁黄网站禁片免费观看直播| 一边亲一边摸免费视频| 国产黄色小视频在线观看| 国产视频首页在线观看| 色噜噜av男人的天堂激情| 久久精品91蜜桃| 三级国产精品欧美在线观看| 亚洲精品久久久久久婷婷小说 | 欧美日韩综合久久久久久| 欧美精品一区二区大全| 男人舔女人下体高潮全视频| 长腿黑丝高跟| 少妇裸体淫交视频免费看高清| 国模一区二区三区四区视频| 久久精品国产亚洲网站| 级片在线观看| 天天一区二区日本电影三级| 欧美一区二区精品小视频在线| 亚洲av.av天堂| 日本欧美国产在线视频| 中文字幕人妻熟人妻熟丝袜美| 中文资源天堂在线| av国产免费在线观看| 麻豆国产97在线/欧美| 成人av在线播放网站| 亚洲精华国产精华液的使用体验 | 久久人妻av系列| 国产免费一级a男人的天堂| 淫秽高清视频在线观看| 中文字幕制服av| 欧美日韩一区二区视频在线观看视频在线 | 成人特级av手机在线观看| 成人鲁丝片一二三区免费| 国产精品一区二区在线观看99 | 国产高潮美女av| 嫩草影院精品99| 国产精品蜜桃在线观看 | av视频在线观看入口| 乱码一卡2卡4卡精品| 边亲边吃奶的免费视频| 国产精品女同一区二区软件| 国产精品永久免费网站| 亚洲欧美精品自产自拍| 超碰av人人做人人爽久久| 亚洲人成网站在线播| 亚洲电影在线观看av| 噜噜噜噜噜久久久久久91| 精品99又大又爽又粗少妇毛片| 中文亚洲av片在线观看爽| 一边亲一边摸免费视频| 特大巨黑吊av在线直播| 亚洲第一区二区三区不卡| 激情 狠狠 欧美| 一卡2卡三卡四卡精品乱码亚洲| 国产熟女欧美一区二区| 九九热线精品视视频播放| 蜜桃亚洲精品一区二区三区| 高清午夜精品一区二区三区 | 看免费成人av毛片| 久久精品影院6| 高清午夜精品一区二区三区 | 日本熟妇午夜| 亚洲一级一片aⅴ在线观看| 亚洲人与动物交配视频| 伊人久久精品亚洲午夜| 久久精品久久久久久噜噜老黄 | 可以在线观看毛片的网站| 2022亚洲国产成人精品| 免费搜索国产男女视频| 青春草视频在线免费观看| 亚洲国产精品sss在线观看| 最近手机中文字幕大全| 欧美日本视频| 免费av毛片视频| 热99re8久久精品国产| 久久鲁丝午夜福利片| 99热只有精品国产| 国产精品伦人一区二区| 国产极品精品免费视频能看的| 噜噜噜噜噜久久久久久91| 别揉我奶头 嗯啊视频| 日韩人妻高清精品专区| 日日摸夜夜添夜夜爱| 欧美最黄视频在线播放免费| 少妇丰满av| 国产精品久久久久久精品电影小说 | 亚洲国产精品合色在线| 长腿黑丝高跟| 精品99又大又爽又粗少妇毛片| 日韩欧美 国产精品| 亚洲欧美日韩卡通动漫| 日本一本二区三区精品| 久久99蜜桃精品久久| 一边摸一边抽搐一进一小说| 尾随美女入室| 国产男人的电影天堂91| 中文字幕免费在线视频6| 精品一区二区三区人妻视频| av在线播放精品| 亚洲在线观看片| 日韩欧美精品v在线| 久久久久九九精品影院| 国产成人一区二区在线| 天堂√8在线中文| 久久久国产成人精品二区| 全区人妻精品视频| 青青草视频在线视频观看| 尤物成人国产欧美一区二区三区| 99国产极品粉嫩在线观看| 国模一区二区三区四区视频| 亚洲人成网站在线观看播放| 亚洲欧美成人综合另类久久久 | 日本撒尿小便嘘嘘汇集6| 高清午夜精品一区二区三区 | 国产精品久久久久久久电影| 一级毛片久久久久久久久女| 国产探花在线观看一区二区| 午夜a级毛片| 国产美女午夜福利| 国产熟女欧美一区二区| av在线播放精品| 国产av麻豆久久久久久久| 男女下面进入的视频免费午夜| 欧美xxxx性猛交bbbb| 国产黄片美女视频| 一级毛片久久久久久久久女| 一级毛片aaaaaa免费看小| 男女下面进入的视频免费午夜| 51国产日韩欧美| 女同久久另类99精品国产91| 青青草视频在线视频观看| 欧美一级a爱片免费观看看| 男人舔女人下体高潮全视频| 国产视频内射| av在线蜜桃| 天天躁日日操中文字幕| 尤物成人国产欧美一区二区三区| 你懂的网址亚洲精品在线观看 | 3wmmmm亚洲av在线观看| 午夜福利在线观看吧| 国产在视频线在精品| 网址你懂的国产日韩在线| 久久久成人免费电影| 99久久无色码亚洲精品果冻| 色尼玛亚洲综合影院| 99视频精品全部免费 在线| 亚洲欧洲国产日韩| 男女视频在线观看网站免费| 在线播放国产精品三级| 国产黄片美女视频| 亚洲欧洲国产日韩| 日本一二三区视频观看| 久久久久久久亚洲中文字幕| 成人特级黄色片久久久久久久| 亚洲av免费在线观看| 1024手机看黄色片| 日日摸夜夜添夜夜添av毛片| 国产av不卡久久| 久久精品国产鲁丝片午夜精品| 国产真实伦视频高清在线观看| 麻豆成人午夜福利视频| 成人特级黄色片久久久久久久| 99国产精品一区二区蜜桃av| 国产伦理片在线播放av一区 | 国内久久婷婷六月综合欲色啪| 亚洲精品久久久久久婷婷小说 | 蜜桃亚洲精品一区二区三区| 午夜福利在线在线| 可以在线观看的亚洲视频| 夜夜看夜夜爽夜夜摸| 亚洲七黄色美女视频| 免费av观看视频| 一边亲一边摸免费视频| 日本一本二区三区精品| www.色视频.com| 久久精品国产99精品国产亚洲性色| 日韩一本色道免费dvd| 给我免费播放毛片高清在线观看| 成人亚洲欧美一区二区av| av在线天堂中文字幕| 亚洲三级黄色毛片| 高清日韩中文字幕在线| 久久精品国产亚洲av天美| 2021天堂中文幕一二区在线观| 好男人在线观看高清免费视频| www.av在线官网国产| 中文字幕熟女人妻在线| 成人一区二区视频在线观看| 五月玫瑰六月丁香| 国产高清三级在线| 高清日韩中文字幕在线| 国产乱人偷精品视频| 日本色播在线视频| 性欧美人与动物交配| 91午夜精品亚洲一区二区三区| 亚洲欧美清纯卡通| 美女脱内裤让男人舔精品视频 | 国产伦在线观看视频一区| 97在线视频观看| 精品国内亚洲2022精品成人| 亚洲国产欧洲综合997久久,| 国产综合懂色| 日韩制服骚丝袜av| 欧美极品一区二区三区四区| 精品久久久久久久久亚洲| 欧美色欧美亚洲另类二区| 在线观看av片永久免费下载| 能在线免费观看的黄片| 国产精品综合久久久久久久免费| 麻豆国产av国片精品| 成人特级黄色片久久久久久久| 久久午夜福利片| 亚洲在久久综合| 一本一本综合久久| 亚洲人成网站在线播放欧美日韩| 亚洲高清免费不卡视频| .国产精品久久| 91在线精品国自产拍蜜月| 小蜜桃在线观看免费完整版高清| 一级毛片电影观看 | 色5月婷婷丁香| 97在线视频观看| 亚洲丝袜综合中文字幕| 又粗又硬又长又爽又黄的视频 | 久久精品国产亚洲av香蕉五月| 国产69精品久久久久777片| 男女啪啪激烈高潮av片| 中文字幕精品亚洲无线码一区| 人妻夜夜爽99麻豆av| av卡一久久| 亚洲色图av天堂| 91在线精品国自产拍蜜月| 熟妇人妻久久中文字幕3abv| 精品免费久久久久久久清纯| 欧美日本视频| 一级毛片久久久久久久久女| 亚洲在久久综合| 观看美女的网站| 成人永久免费在线观看视频| 欧美一区二区亚洲| 一个人看视频在线观看www免费| 黄色视频,在线免费观看| 日韩一区二区视频免费看| 亚洲内射少妇av| 成人一区二区视频在线观看| 日韩欧美三级三区| 亚洲av成人精品一区久久| 黑人高潮一二区| 国产日韩欧美在线精品| 五月玫瑰六月丁香| 亚洲在线自拍视频| 少妇的逼好多水| 丝袜喷水一区| 久久人人爽人人爽人人片va| 看片在线看免费视频| 九色成人免费人妻av| 可以在线观看毛片的网站| 精品久久久久久久久av| 天堂av国产一区二区熟女人妻| АⅤ资源中文在线天堂| 国产在线男女| 欧美性感艳星| 伊人久久精品亚洲午夜| 色播亚洲综合网| 岛国毛片在线播放| 夜夜爽天天搞| 变态另类成人亚洲欧美熟女| 最近手机中文字幕大全| 1000部很黄的大片| 午夜激情福利司机影院| 只有这里有精品99| 亚洲欧美精品综合久久99| 91av网一区二区| 国产精品久久久久久久久免| 亚洲欧洲国产日韩| 国产 一区 欧美 日韩| av免费在线看不卡| 国产亚洲av片在线观看秒播厂 | 人体艺术视频欧美日本| 久久精品夜夜夜夜夜久久蜜豆| 插阴视频在线观看视频| 国产色婷婷99| 深夜a级毛片| 亚洲成人久久爱视频| 三级男女做爰猛烈吃奶摸视频| 成人漫画全彩无遮挡| 尤物成人国产欧美一区二区三区| 国产真实伦视频高清在线观看| 精品一区二区三区视频在线| 国产免费男女视频| 欧美精品国产亚洲| 麻豆乱淫一区二区| 波野结衣二区三区在线| 久久综合国产亚洲精品| 观看免费一级毛片| 大型黄色视频在线免费观看| 午夜福利在线观看吧| 日韩欧美在线乱码| 国产精品,欧美在线| 亚洲精品456在线播放app| 欧美精品一区二区大全| 亚洲精品影视一区二区三区av| 亚洲成av人片在线播放无| 免费av毛片视频| 午夜福利成人在线免费观看| 国产爱豆传媒在线观看| 亚洲精品久久国产高清桃花| 亚洲成av人片在线播放无| 中文精品一卡2卡3卡4更新| 干丝袜人妻中文字幕| 男的添女的下面高潮视频| 亚洲精品影视一区二区三区av| 国产成人精品一,二区 | 人妻夜夜爽99麻豆av| 美女xxoo啪啪120秒动态图| 一本精品99久久精品77| 日本与韩国留学比较| 男插女下体视频免费在线播放| 婷婷亚洲欧美| a级毛片免费高清观看在线播放| 亚洲综合色惰| 国产一级毛片在线| 国产真实伦视频高清在线观看| 一卡2卡三卡四卡精品乱码亚洲| 亚洲av男天堂| 国产探花在线观看一区二区| 欧美性感艳星| 波野结衣二区三区在线| 亚洲欧美中文字幕日韩二区| 国产亚洲5aaaaa淫片| 国产单亲对白刺激| 91麻豆精品激情在线观看国产| 国产探花在线观看一区二区| 免费大片18禁| 小说图片视频综合网站| 亚洲国产色片| 2021天堂中文幕一二区在线观| 亚洲av电影不卡..在线观看| 亚洲自偷自拍三级| 国产精品不卡视频一区二区| 成人午夜高清在线视频| 国产午夜福利久久久久久| 午夜激情欧美在线| 色噜噜av男人的天堂激情| 观看免费一级毛片| 日韩强制内射视频| 久久久久久久久久久免费av| 午夜精品在线福利| 久久99蜜桃精品久久| 成年av动漫网址| av又黄又爽大尺度在线免费看 | 免费无遮挡裸体视频| 性色avwww在线观看| 国内少妇人妻偷人精品xxx网站| 成人鲁丝片一二三区免费| 久久婷婷人人爽人人干人人爱| av在线老鸭窝| 成人漫画全彩无遮挡| h日本视频在线播放| 久久久久网色| 亚洲精品日韩av片在线观看| 久久久a久久爽久久v久久| 亚洲无线在线观看| 三级经典国产精品| 久99久视频精品免费| 波多野结衣高清无吗| 亚洲久久久久久中文字幕| 亚洲国产欧洲综合997久久,| 欧美人与善性xxx| 能在线免费看毛片的网站| 精品人妻偷拍中文字幕| 亚洲精品456在线播放app| 我的女老师完整版在线观看| 国产在线男女| av卡一久久| 欧美一区二区精品小视频在线| 国产精品伦人一区二区| 亚洲精品色激情综合| 日韩欧美在线乱码| 久久午夜福利片| 精品人妻偷拍中文字幕| 精品99又大又爽又粗少妇毛片| 中文精品一卡2卡3卡4更新| 国产伦一二天堂av在线观看| 男插女下体视频免费在线播放| 2022亚洲国产成人精品| 色尼玛亚洲综合影院| 少妇熟女aⅴ在线视频| 高清毛片免费观看视频网站| 亚洲av中文av极速乱| 亚洲美女搞黄在线观看| 国国产精品蜜臀av免费| 亚洲国产精品合色在线| 亚洲最大成人手机在线| 国产精品福利在线免费观看| 国产大屁股一区二区在线视频| 国产视频首页在线观看| 在线a可以看的网站| 欧美色视频一区免费| 美女大奶头视频| 老女人水多毛片| 嫩草影院精品99| 日本成人三级电影网站| 51国产日韩欧美| 热99在线观看视频| 欧美变态另类bdsm刘玥| 91久久精品国产一区二区成人| 寂寞人妻少妇视频99o| 国产单亲对白刺激| 国产男人的电影天堂91| 国内精品一区二区在线观看| 国产精品久久久久久精品电影小说 | 97人妻精品一区二区三区麻豆| av在线老鸭窝| 观看美女的网站| 永久网站在线| 极品教师在线视频| 欧美精品国产亚洲| 九草在线视频观看| 国产精品美女特级片免费视频播放器| eeuss影院久久| 国产欧美日韩精品一区二区| 夜夜爽天天搞| 神马国产精品三级电影在线观看| 亚洲图色成人| 亚洲精品国产成人久久av| h日本视频在线播放| 热99re8久久精品国产| 久久精品夜夜夜夜夜久久蜜豆| a级一级毛片免费在线观看| 夜夜爽天天搞| 日日啪夜夜撸| 级片在线观看| 综合色丁香网| 一区二区三区高清视频在线| 99久国产av精品| 国产男人的电影天堂91| 国产精品一区二区三区四区免费观看| 国产成人aa在线观看| 日韩精品有码人妻一区| 免费一级毛片在线播放高清视频| 91久久精品国产一区二区成人| 日韩一本色道免费dvd| 久久精品国产鲁丝片午夜精品| 中国国产av一级| 精品熟女少妇av免费看| 一级av片app| 变态另类丝袜制服| 大香蕉久久网| 国产精品美女特级片免费视频播放器| 菩萨蛮人人尽说江南好唐韦庄 | 国产精品1区2区在线观看.| 一级黄片播放器| 国产成人91sexporn| 国产亚洲精品av在线| 久久九九热精品免费| 久久国产乱子免费精品| 日韩一区二区视频免费看| 国产精品久久视频播放| 久久人人精品亚洲av| 亚洲三级黄色毛片| 亚洲精品影视一区二区三区av| 蜜臀久久99精品久久宅男| 国产亚洲av片在线观看秒播厂 | 午夜a级毛片| 免费av观看视频| 给我免费播放毛片高清在线观看| 久久国产乱子免费精品| 天堂av国产一区二区熟女人妻| 能在线免费看毛片的网站| 亚洲国产精品sss在线观看| 成人综合一区亚洲| 亚洲婷婷狠狠爱综合网| 91aial.com中文字幕在线观看| 99热精品在线国产| 欧美成人一区二区免费高清观看| 免费看a级黄色片| 青春草视频在线免费观看| 精品久久久久久久末码| 久久99精品国语久久久| 成人综合一区亚洲| 亚洲婷婷狠狠爱综合网| 国产一区二区三区av在线 | av视频在线观看入口| 亚洲精品自拍成人| 亚洲av成人精品一区久久| 免费搜索国产男女视频| 国产三级在线视频| 国产色婷婷99| 一区二区三区免费毛片| 国内少妇人妻偷人精品xxx网站| 国产单亲对白刺激| 久久久久久伊人网av| 午夜激情福利司机影院| 国产成人一区二区在线| 久久综合国产亚洲精品| 国产白丝娇喘喷水9色精品|